- Tytuł:
- A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
- Autorzy:
- Źródło:
- Cancer Immunology, Immunotherapy. 69(12):2589-2598
Czasopismo naukowe